Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00675064 | Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects | PHASE1 | COMPLETED | 41 | — | — | May 2, 2008 | Oct 12, 2008 | Sep 13, 2018 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Anti-malarial experimental drug | EXPERIMENTAL | After randomization subjects will receive either 5, 25, 100, 250, 500, 1000, 2000 and 3000 mg of GSK3697969 orally . GSK3697969 will be available as 5, 25 and 250 mg capsules. |
| Matching placebo | ACTIVE_COMPARATOR | After randomization subjects will receive matching placebo of GSK3697969. |
| Name | Type | Description |
|---|---|---|
| GSK369796 | DRUG | Anti-malarial |
| Placebo | DRUG | Placebo matching GSK369796 |
Inclusion Criteria: * Healthy adults between the ages of 18 to 40, inclusive. * Female subjects must be of non-childbearing potential including pre-menopausal females with documented (medical report verification) hysterectomy or bilateral oophrectomy or postmenopausal defined as 6 months of spontan...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 4 | PHASE3 | Tafenoquine, Primaquine, Chloroquine, GSK3772701, RTS,S/AS01E vaccine |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | INE963, KAE609, KLU156 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |